Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Gañán‐Gómez, Simona Colla|Nature Medicine|2022Cited by 81
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemiaGuillermo Montalban‐Bravo, Simona Colla|Cell Reports Medicine|2024Cited by 14
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantationHidetaka Uryu, Koichi Takahashi, Zongrui Li et al.|Nature Genetics|2025Cited by 10
Clonal evolution of hematopoietic stem cells after cancer chemotherapyHidetaka Uryu, Koichi Takahashi, Koichi Saeki et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 6
Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromesJuan José Rodríguez‐Sevilla, Simona Colla|Nature Communications|2025Cited by 6